Showing results (191-200 of 208) with videos related to
Sort By:
Pageof 21
Clinical Journal of the American Society of Nephrology : CJASN|August 19, 2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow, Lara B Pupim, Geoffrey A Block, et al.Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.Kidney360|September 23, 2025
A Metabolomics Approach to Identify Metabolites Associated with Uremic Symptoms in Patients Receiving Maintenance HemodialysisSolaf Al Awadhi, Leslie Myint, Eliseo Guallar, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.Eclinicalmedicine|September 10, 2024
Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extensionSmeeta Sinha, Sagar U Nigwekar, Vincent Brandenburg, et al.Life (Basel, Switzerland)|April 1, 2020
Implementation of a Renal Precision Medicine Program: Clinician Attitudes and AcceptanceKatherine M Spiech, Purnima R Tripathy, Alex M Woodcock, et al.Kidney International Reports|June 13, 2022
Vasopressin for Post-kidney Transplant HypotensionMuhammad Y Jan, Sharon M Moe, Oluwafisayo Adebiyi, et al.The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trialPatrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.Journal of the American Heart Association|November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trialDavid C Wheeler, Gerard M London, Patrick S Parfrey, et al.The New England Journal of Medicine|November 6, 2012
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, Glenn M Chertow, Geoffrey A Block, et al.Pageof 21